Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines

1 december 2006 PRESS RELEASE Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines Leiden, The Netherlands, December 1, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has been awarded contracts totaling over US $230 million for its Quinvaxem(TM) and Hepavax-Gene® paediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those three years. Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries. Quinvaxem(TM), a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell's laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children. Current demand for the Quinvaxem® vaccine exceeds 50 million doses. The total market potential is 150 million doses per year in 3 to 4 years. The Hepavax-Gene®, recombinant hepatitis B vaccine, is one of the WHO's pre-qualified vaccines for active immunization against the hepatitis B virus. Young children infected with HBV are the most likely to develop chronic infections. Hepavax-Gene® was internationally introduced in 1996 and has become one of today's major hepatitis B vaccines supplied to more than 90 countries. "The multiple year contracts that the supranational organizations have granted to Crucell, underline Crucell's position as a leading supplier of important vaccines. Quinvaxem(TM) is the first internationally available fully-liquid vaccine containing these five life saving antigens and it will make a significant contribution to children's vaccination programs in the developing world," stated Crucell's CEO, Dr Ronald H.P. Brus. "Quinvaxem(TM) will be an important contributor to the Company's 2006 total revenues, estimated between EUR 140 million - EUR 150 million and its aim to achieve cash break-even in 2007." About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com. Forward-looking statements This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS). For further information please contact: Crucell N.V. Leonard Kruimer Chief Financial Officer Tel. +31 (0)71 524 8722 l.kruimer@crucell.com Paul Vermeij Director Investor Relations and Corporate Communications Tel. +31 (0)71 524 8718 p.vermeij@crucell.com For Crucell in the US: Redington, Inc. Thomas Redington Tel. +1 212-926-1733 tredington@redingtoninc.com